In a randomized study by Kuhadia et al,27 involving 72 individuals (placebo = 18, liraglutide = 54) with T1D, who were overweight or had obesity, the addition of liraglutide (1.2, 1.8 mg) to insulin over a 12-week period resulted in modest reductions in average blood glucose, HbA1c, small reductions in insulin doses, significant weight loss, decreased postprandial glucose concentration, and frequent gastrointestinal (GI) side effects. The gene discussed is INS; the disease is Obesity.